

STATE OF NEW HAMPSHIRE

Honorarium or Expense Reimbursement Report (RSA 15-B)



Type or Print all Information Clearly:

Name: GM MONAWAR HOSAIN Work Phone No. 603 271 7812

Work Address: 29 HAZEN DR. CONCORD, NH 03301

Office/Appointment/Employment held: PROGRAM PLANNER (CANCER EPIDEMIOLOGIST)

List the full name, post office address, occupation, and principal place of business, if any, of the source of any reportable honorarium or expense reimbursement. When the source is a corporation or other entity, the name and work address of the person representing the corporation or entity in making the honorarium or expense reimbursement must be provided in addition to the name of the corporation or entity.

Source of Honorarium or Expense Reimbursement:

Name of source: First Middle Last

Post Office Address:

Occupation:

Principal Place of Business:

If source is a Corporation or other Entity:

Name of Corporation or Entity: AVAHO (ASSOCIATION OF VA HEMATOLOGY & ONCOLOGY)

Name of Corporate/Entity Representative: SUSAN LENTZ

Work Address of Representative: 4601 223RD ST. SW, MOUNTLAKE TERRACE, WA 98043

Food and/or beverages consumed pursuant to RSA 15-B:6, II with value over \$25.00

Value of Honorarium: Date Received: If exact value is unknown, provide an estimate of the value of the gift or honorarium and identify the value as an estimate. Exact Estimate

Value of Expense Reimbursement: 693.80 Date Received: 10/4-10/6/2013 A copy of the agenda or an equivalent document must be attached to this filing. Exact Estimate Hotel and Airfare

Briefly describe the service or event this Honorarium or Expense Reimbursement relates to:

TO PRESENT AN ABSTRACT AND ATTENDING 9th AVAHO ANNUAL CONFERENCE, ATLANTA, GA

"I have read RSA 15-B and hereby swear or affirm that the foregoing information is true and complete to the best of my knowledge and belief."

Signature of Filer: M Hosain

Date Filed: 10/10/2013

9/07

RSA 15-B:9 Penalty. Any person who knowingly fails to comply with the provisions of this chapter or knowingly files a false report shall be guilty of a misdemeanor.

Return to: Secretary of State's Office, State House Room 204, Concord, NH 03301

RECEIVED OCT 11 2013 NEW HAMPSHIRE DEPARTMENT OF STATE

ASSOCIATION OF VA HEMATOLOGY/ONCOLOGY

9th ANNUAL MEETING

October 4 – 6, 2013

Marriott Marquis, Atlanta, GA

PROGRAM AGENDA

FRIDAY, OCTOBER 4, 2013

1:00 – 6:00 pm Registration
1:00 – 6:00 pm Exhibitor Set-up
1:00 – 3:00 pm AVAHO Board Meeting

MYELOMA MINI-SYMPOSIUM (Moderator: Maria Ribeiro, MD)

3:00 – 3:30 pm **HOW I TREAT MYELOMA**
Jonathan L. Kaufman, MD
Associate Professor, Associate Vice Chair for Quality
Department of Hematology and Medical Oncology
Winship Cancer Institute of Emory University

1. Review how to establish the diagnosis of myeloma and prognosis
2. Review optimal induction therapy for the newly diagnosed patient, both transplant and non- transplant patients
3. Review management of patients with relapsed disease

3:30 – 3:50 pm **COST OF ORAL CHEMOTHERAPY**
Hamideh Tavakoli-Ahmady, Pharm.D.
Hematology/Oncology Clinical Pharmacy Program Manager
Medical Oncology Clinic, VA Loma Linda HCS Cancer Center
Loma Linda, CA

1. Assess the cost-effectiveness of multiple myeloma regimens including patient selection for oral chemotherapy
2. Summarize the advantages and disadvantages of oral chemotherapy including the financial concerns involving these agents

3:50 – 4:10 pm **DEMOGRAPHICS OF MYELOMA: VETERANS AFFAIRS COMPARED TO ALL ACOS HOSPITALS 2000 TO 2010**
Barbara Cunningham, CTR
Grace Registry Services, VA Buffalo, NY

1. Overview patients with Multiple Myeloma in the Veterans Affairs as well as in all ACOS Hospitals

4:10 – 4:30 pm **MAJOR PSYCHOSOCIAL RESOURCES AVAILABLE THROUGH NATIONAL ORGANIZATIONS**
Moderator: Kelli Essex
Rosalinda Ramirez, Lymphoma and Leukemia Society

Ryan Branch, American Cancer Society
Atlanta Area Multiple Myeloma Support Group

1. At the end of this session the attendees will be able to identify available community resources for caregiver and patients with cancer
2. The attendees will be able to better refer patients with new diagnosis of myeloma and other cancers to major National Organizations Programs for cancer education of support.

4:30 – 5:00 pm
ERA OF NEW

WHICH MYELOMA PATIENT SHOULD GET BONE MARROW TRANSPLANT IN THIS ERA OF TARGETED THERAPIES?

Cesar Freytes, MD

Director, Bone Marrow Transplant Program

Audie L. Murphy Memorial Veterans Hospital, San Antonio, TX

1. Identify when to consider autologous stem cell transplant for patients with myeloma
2. Understand current non-transplant and transplant treatment strategies

5:00 – 5:15 pm

Symposium Q&A

FRIDAY EVENING KEYNOTE PRESENTATION

6:30 – 7:00 pm

CURRENT TREATMENT OF VENOUS THROMBOEMBOLISM

Kenneth Bauer, MD

Professor of Medicine, Harvard Medical School, Boston, MA

Chief, Hematology Section, VA Boston Healthcare System

1. Discuss different approaches to treat acute venous thromboembolism (VTE) including the active cancer population.
2. Summarize arguments for and against long-term thromboprophylaxis in patients with a first unprovoked VTE.
3. Assess the applicability of novel oral anticoagulants for the routine care of VTE.

7:00 – 8:30 pm

AVAHO Reception

SATURDAY, OCTOBER 5, 2013

7:00 – 5:00 pm

Registration

7:00 – 5:00 pm

Exhibit Displays

7:00 – 5:00 pm

General Poster Session

7:00 – 8:00 am

Breakfast Buffet

8:00 – 8:05 am

WELCOME/INTRODUCTION

Maria Ribeiro, MD – President

SESSION I: HEAD AND NECK (Moderator: Ace Allen, MD)

8:05 – 8:35 am

WHAT IS NEW IN HEAD & NECK

Barbara Murphy, MD

Professor of Medicine, Division of Hematology/Oncology, Vanderbilt University School of Medicine, Nashville, TN

1. Describe the data on targeted therapy for squamous cell carcinoma of the head and neck.
2. Explain the role of HPV positivity in the prognostication of patients with oropharyngeal squamous cell carcinoma.

8:35 – 9:05 am

PSYCHOLOGICAL DISTRESS AFTER CANCER TREATMENT

Jennifer Moye, Ph.D.

Director, Geriatric Mental Health, VA Boston Healthcare System
Associate Professor, Harvard Medical School

1. Describe the prevalence and optimal screening for depression after cancer
2. List three domains of worry and their significance for physical health
3. Define post traumatic growth

9:05 – 9:35 am

CANCER REHABILITATION: IMPROVING THE FUNCTIONAL HEALTH OF HEAD AND NECK CANCER PATIENTS

Sarah Eickmeyer, MD

Assistant Professor, Physical Medicine and Rehabilitation
Medical College of Wisconsin, Zablocki VA Medical Center

1. Define the role of psychiatry in cancer care and rehabilitation.
2. Understand the unmet functional needs of cancer patients.
3. Review common functional and rehabilitation issues in the head and neck cancer population.

9:35 – 9:45 am

Questions and Answers

9:45 – 10:15 am

Break/Exhibits

SESSION II: BLOOD DISORDERS (Moderator- Joao Ascensao, MD PhD)

10:15 – 10:45 am

ACQUIRED BLEEDING DISORDERS

Christine L. Kempton, MD, MSc

Assistant Professor, Department of Pediatrics and Department of Hematology/Oncology

Director, Hemostasis and Thrombosis Program

Aflac Cancer and Blood Disorders Center

Emory University School of Medicine

1. Describe common clinical presentations of patients with acquired coagulation disorders.
2. Identify the appropriate laboratory work-up of patients with suspected acquired coagulation disorders.
3. Define initial therapeutic approaches for patients with acquired coagulation disorders.

10:45 – 11:15 am

CANCER-ASSOCIATED THROMBOSIS

Frederick R. Rickles, MD, FACP

Professor of Medicine, Pediatrics and Pharmacology and Physiology
The George Washington University

1. Articulate the data in support of the relative risk models for predicting thrombosis in cancer
2. Articulate the role for anticoagulant prophylaxis in cancer
3. Articulate the pros and cons of the use of novel oral anticoagulants (NOACs) in thrombosis

11:15 – 11:45 am TARGETED THERAPY OF CHRONIC LYMPHOCYTIC LEUKEMIA

Adrian Wiestner, MD, PhD

Investigator and Attending Physician

Hematology Branch, National, Heart, Lung and Blood Institute

National Institutes of Health, Bethesda, MD

1. Obtain an overview of new insights into the pathogenesis of CLL.
2. Be able to discuss drug-able targets in CLL.
3. Be able to assess pro and cons of targeted treatment options for their patients.

11:45 -12:00 pm Questions and Answers

12:00 – 12:30 pm VISION FOR THE FUTURE...LEAD, INSPIRE, EMPOWER IN ONCOLOGY NURSING

Mary Gullatte, PhD, RN, ANP-BC, AOCN, FAAN

Vice President for Patient Services and Chief Nursing Officer

Emory University Hospital Midtown

President, Oncology Nursing Society

1. Identify key metrics driving change in current oncology practice
2. Discuss strategies for practice success in the future
3. Discuss inter-professional team collaboration as a success strategy to care coordination

12:30 – 1:30 pm Lunch/Business Meeting

CONCURRENT SESSION: UPDATES I (Moderator: Steven H Krasnow, MD)

1:30 – 2:00 pm GLIOBLASTOMA

David Cory Adamson, MD, PhD, MHSc, MPH

Associate Professor of Surgery, Associate Professor in Neurobiology

Duke University, VA Durham, Durham, NC

1. Current treatment recommendations for Glioblastoma
2. Current areas of active investigation

2:00 – 2:30 pm MELANOMA UPDATE

David H. Lawson, MD

Professor of Hematology and Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA

1. Discuss indications for adjuvant interferon and merits of the 2 FDA approved regimens.

2. Discuss current and pending targeted and immunotherapeutic agents for treatment of advanced disease.
3. Discuss timing of different systemic therapies for advanced disease.

2:30 – 3:00 pm **CURRENT AND EMERGENT MOLECULAR TARGETS IN LUNG CANCER THERAPY**

Assistant Professor of Hematology and Oncology

Emory University, Winship Cancer Institute, Atlanta, GA

1. Understand current FDA approved molecularly targeted therapies for NSCLC.
2. Understand mechanisms of resistance to these approved therapies.
3. Understand emerging molecularly targeted therapies.

3:15 – 3:30 pm Questions and answers

CONCURRENT SESSIONS: UPDATES II (Moderator: Ellen Ballard, RN)

1:30 – 2:15 pm **PSYCHOSOCIAL ISSUES COMMONLY SEEN IN ONCOLOGY**

Veronica Reis, PhD

Staff Psychologist/Health Behavior Coordinator

VA Palo Alto, Palo Alto, CA

1. Identify at least 3 psychosocial issues commonly seen in Oncology.
2. Identify at least 3 ways psychosocial issues might impact a patient's treatment adherence.
3. Identify at least 3 resources to assist Oncology patients and their families w/ increased adherence and QoL.

2:15 – 3:00 pm **PATIENT NAVIGATION-OH THE PLACES YOU'LL GO!**

Laura Hunnibell, APRN

Dayton VA Medical Center, Dayton, OH

1. Describe what is patient navigation?
2. Describe the various settings and roles for nurse navigation.
3. Describe the importance of data collection and the four metrics common to patient navigation.

3:00 – 3:30 pm Questions and answers

3:30 – 4:00 pm **BREAK/VISIT EXHIBITORS**

SESSION IV: VA DATABASES & TUMOR REGISTRY (Moderator: Theresa Gillespie)

4:00 – 4:20 pm **A MILLION COOPERATIVE DATABASES**

Michael J. Kelley, MD

National Program Director for Oncology/SCS/PCS

Chief, Hematology/Oncology Durham VAMC

Associate Professor of Medicine, Duke University, Durham, NC

1. Understand the value of various databases for research.

4:20 – 4:40 pm **USING VA CENTRAL TUMOR REGISTRY FOR CLINICAL RESEARCH**

Kenneth Carson, MD
Assistant Professor, Department of Internal Medicine
Division of Medical Oncology
Washington University School of Medicine, St. Louis, Missouri

1. Understand the utility of the VA central cancer registry for outcomes research.

4:40 – 5:00 pm

RAPID QUALITY REPORTING SYSTEM (RQRS)

Donna Connery, CTR

Cancer Registrar, VA Connecticut Healthcare System, West Haven, CT

1. Introduction to RQRS - including history of RQRS.
2. Utilizing the RQRS data in your facility.
3. What are the benefits of RQRS?
4. 2012 Standards - VA Designed Tools.

5:00 – 6:00 pm

BREAKOUT SESSIONS

- Breakout 1 Physicians –Saramma Alexander, MD
- Breakout 2 Nurses - Lori Hoffman Hogg, RN, MSN
- Breakout 3 Pharmacists - Sean Cosgriff, PharmD
- Breakout 4 Tumor Registrars - Barb Cunningham/Donna Connery
- Breakout 5 Radiation Oncology – Ruchika Gutt, MD

6:00 – 7:00 pm

RECEPTION/EXHIBIT DISPLAYS/POSTER

7:30 – 9:30 pm

ANNUAL DINNER/PRESIDENTIAL ADDRESS: Dr. Maria Ribeiro

KEYNOTE SPEAKER: Otis Brawley, MD, FACP, Chief Medical Officer, American Cancer Society

SUNDAY, OCTOBER 6, 2013

7:00 – 12:00 pm

Registration

7:00 – 12:00 pm

Exhibit Displays

7:00 – 12:00 pm

General Poster Session

7:00 – 8:30 am

Breakfast Buffet

SESSION V: ABSTRACT SESSION (Moderator: Peter Silberstein, MD)

8:00 – 8:15 am

**UTILIZING CANCER REGISTRY DATA TO DERIVE TREATMENT SUMMARIES
REQUIRED FOR ACOS ACCREDITATION BY 2015**

Gigi White, CTR; David Hall, MD; Paulette Mehta, MD

Central Arkansas Veterans Healthcare System, Little Rock, AR

1. Introduce and demonstrate how CAVHS derived cancer treatment summaries utilizing data collected in cancer registries.
2. Summarize and evaluate pilot results

3. Discuss benefits and limitations of using cancer registry data

8:15 – 8:30 am

IMPACT OF IMPLEMENTING A HEMATOLOGY/ONCOLOGY ORAL MEDICATION MANAGEMENT CLINIC

Bailey Crandall, PharmD, BCPS; Muoi Gi, PharmD, BCPS, BCOP; Brian Dahl, BCOP; Tom Cookson, PharmD

VA San Diego Healthcare System, San Diego, CA

1. Describe strategies used to successfully implement a Hematology/Oncology Oral Medication Management Clinic at VA San Diego.

8:30 – 8:45 am

IMPROVING GENETIC TESTING VIA TELE-HEALTH

Carrie L. Kairys, DNP, FNP-BC and Becki Hulinsky, MS, LCGC

West Palm Beach VA Medical Center and VHA Central Office: Genomic Medicine Service, West Palm Beach, FL

1. Identify how genetic counseling from GMS can improve Veterans access to genetic services at VA facilities

8:45 – 9:00 am

USE OF CISPLATIN IN THE TREATMENT OF METASTATIC LUNG CANCER DOES NOT LEAD TO AN IMPROVED SURVIVAL AND IS ASSOCIATED WITH A HIGHER INCIDENCE OF TOXICITIES

Rafael Santana-Davila, Carlos Arce-Lara, Christine Williams, Michael Kelley, Jeffrey Whittle

Medical College of Wisconsin and the Zablocki VA, Milwaukee, WI

1. Discuss the use of different chemotherapy agents and their use in metastatic lung cancer and their association with outcomes.

9:00 – 9:15 am

A MULTIDISCIPLINARY CREATION OF A SURVIVORSHIP CLINIC FOR PATIENTS WITH COLORECTAL CANCER

Janet Cameron, MSN, AOCN, Freeman, Nancy, MD, Nancy Crandall, NP, Annmarie Dunican, MD, Maura Flynn, NP, Jennifer Ouellette, NP
Providence VA Medical Center, Providence, RI

1. describe the development and evolution of the Survivorship Clinic

9:15 – 9:45 am

Break/Exhibits

SESSION VI: BREAST CANCER TUMOR BOARD (Moderator: Anita Aggarwal, DO PhD)

9:45 – 10:00 am

PATIENT ADVOCACY IN BREAST CANCER

10:00 – 10:30 am

UPDATES IN THE MANAGEMENT OF BREAST CANCER

Laronna S. Colbert, MD

Assistant Professor, Clinical Medicine

Morehouse School of Medicine, Atlanta, GA

1. Select optimal hormonal therapies in the adjuvant setting for early stage breast cancer.
2. Employ recent data in the selection of directed therapies for the management of Her2 positive breast cancer.

3. Incorporate recent data from clinical trials in the management of patients with metastatic breast cancer.
- 10:30 – 11:00 am** **UPDATE ON THE ONS/ASCO CHEMOTHERAPY ADMINISTRATION GUIDELINES**
 Janet Cogswell, MS, RN, CS, AOCN
 VA NJ Healthcare System, East Orange, NJ
1. Identify the changes made to the ONS/ASCO Guidelines.
 2. Discuss the impact on nursing competencies.
 3. Develop strategies to overcome barriers to implementation.
- 11:00 - 11:30 am** **ROLE OF SNL IN BREAST CANCER/SNL IN NEOADJ AND AFTER NEOADJ: WILL AXILLARY STAGING SOON DISAPPEAR?**
 Edibaldo Silva, MD, PhD, FACS
 Professor, Division of Surgical Oncology, Department of Surgery
 University of Nebraska Medical School, Omaha, NE
1. Understand the impact of ACOS Trial Z0011 on current breast cancer practice.
 2. Understand why it is more important to know what you end up with in the axilla rather than what you begin with in the setting of neo-adjuvant chemotherapy for breast cancer.
- 11:30 – 12:00 pm** **NEW TECHNIQUES FOR RADIATION DELIVERY IN BREAST CANCER**
 Karen Godett, MD
 Associate Professor, Radiation Oncology
 Emory University Hospital Midtown, Atlanta, GA
1. Understanding the rationale for partial breast radiation- the pros and cons vs. standard of care.
 2. Defining hypo-fractionation and examples with external beam radiation
 3. The definition of brachytherapy and how it is currently used in treatment of breast cancer.
- 12:00 – 12:30 pm** **ADDRESSING THE PHYSICAL AND PSYCHOSOCIAL NEEDS OF THE PATIENT WITH BREAST CANCER**
 Lisa D. VanHoose PhD, PT, CLT-LANA
 Assistant Professor
 Director of the Cancer Rehabilitation and Wellness Laboratory
 Co-Director of KU HealthPartners Rehabilitation and Wellness Clinic
 APTA Oncology Section President
1. Recognize potential or actual functional, emotional, psychosocial and physical impairments of breast cancer survivors.
 2. Determine the need for a rehabilitation referral for risk reduction or to address cancer related side effects.
 3. Demonstrate an understanding of rehabilitative strategies for cancer related side effects for improved patient education .
- 12:30 pm** **ADJOURN**
- 12:30 – 2:30 pm** **Board Meeting/Lunch**